For the quarter ending 2025-09-30, EVH had -$34,966K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Loss before preferred dividends and accretion of series a preferred stock including excise tax | -20,864 | -84,515 |
| Change in fair value of contingent consideration | -1,089 | 2,926 |
| Loss (gain) from equity method investees | 156 | 178 |
| Extinguishment of series a preferred stock and other refinancing fees | 6,000 | 9,000 |
| Gain on extinguishment of short-term debt | 431 | - |
| Loss on option exercise | 0 | -52,544 |
| Depreciation and amortization expenses | 23,615 | 47,199 |
| Stock-based compensation expense | 14,682 | 22,661 |
| Deferred tax expense (benefit) | 627 | -570 |
| Amortization of contract cost assets | 3,181 | 2,523 |
| Amortization of deferred financing costs | 2,359 | 2,403 |
| Loss on lease termination | 1,230 | -1,906 |
| Change in tax receivables agreement liability | 0 | 0 |
| Right-of-use operating assets | -505 | -792 |
| Other current operating cash inflows (outflows), net | 0 | 0 |
| Accounts receivable, net and contract assets | 48,561 | -55,925 |
| Prepaid expenses and other current and non-current assets | -2,191 | 1,803 |
| Contract cost assets | 1,837 | 1,649 |
| Accounts payable | 3,312 | 18,189 |
| Accrued liabilities | 1,468 | -5,867 |
| Operating lease liabilities | -9,014 | -20,973 |
| Accrued compensation and employee benefits | 17,118 | 4,543 |
| Deferred revenue | -462 | -174 |
| Reserve for claims and performance-based arrangements | 24,401 | -131,454 |
| Other long-term liabilities | -3 | 803 |
| Net cash and restricted cash (used in) provided by operating activities | 15,812 | -25,769 |
| Cash paid for asset acquisitions and business combinations | -2 | 56,047 |
| Return of equity method investments | 198 | 788 |
| Purchases of investments and contributions to equity method investees | 0 | 1,000 |
| Investments in internal-use software and purchases of property and equipment | 8,962 | 17,365 |
| Net cash and restricted cash used in investing activities | -8,762 | -73,624 |
| Changes in working capital balances related to claims processing | 578 | 44,754 |
| Payment of contingent consideration | 750 | 1,000 |
| Proceeds from stock option exercises | 0 | 0 |
| Proceeds from issuance of long-term debt, net of offering costs | -168,740 | -221,000 |
| Repayment of long-term debt | 166,755 | 62,500 |
| Repurchase of common stock | 39,996 | - |
| Payment of preferred dividends | 1,929 | 9,198 |
| Taxes withheld and paid for vesting of equity awards | 547 | 4,621 |
| Net cash and restricted cash provided by (used in) financing activities | -41,815 | 98,927 |
| Effect of exchange rate on cash and cash equivalents and restricted cash | -201 | -60 |
| Net decrease in cash and cash equivalents and restricted cash | -34,966 | -526 |
| Cash and cash equivalents at beginning of period | 178,496 | - |
| Cash and cash equivalents at end of period | 143,004 | - |
Evolent Health, Inc. (EVH)
Evolent Health, Inc. (EVH)